A turning point in the fight against ovarian cancer?
Mené sur 28 patientes atteintes d'un cancer séreux de l'ovaire de haut grade, ne présentant pas de mutation BRCA et récidivant (âge médian : 64 ans), cet essai de phase II évalue l'efficacité, du point de vue de taux de réponse, et la toxicité du prexasertib, un inhibiteur anti-CHK et CHK2, après l'échec de plusieurs lignes de thérapies (nombre médian de thérapies précédentes : 5)
Ovarian cancer represents the fifth leading cause of death in women, with 5-year survival around 10%. This unfavourable prognosis figures are closely related to intrinsic or acquired resistance to conventional chemotherapy, making the active search of novel agents with relevant molecular targets crucial in the fight against this disease. In The Lancet Oncology, Jung-Min Lee and colleagues1 report the results of a phase 2 study investigating the clinical activity of prexasertib, a cell cycle checkpoint kinase 1 and 2 (CHK1 and CHK2) inhibitor, in recurrent high-grade serous ovarian cancer
The Lancet Oncology 2018